Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain

1987 ◽  
Vol 41 (4) ◽  
pp. 392-401 ◽  
Author(s):  
Charles E Inturrisi ◽  
Wayne A Colburn ◽  
Robert F Kaiko ◽  
Raymond W Houde ◽  
Kathleen M Foley
2003 ◽  
Vol 43 (6) ◽  
pp. 624-636 ◽  
Author(s):  
Daniel Wermeling ◽  
Michael Drass ◽  
David Ellis ◽  
Martha Mayo ◽  
Dawn McGuire ◽  
...  

2020 ◽  
Author(s):  
Natalia A. Anisimova ◽  
Natalia O. Selizarova ◽  
Grigory A. Plisko ◽  
Evgeny D. Semivelichenko ◽  
Svetlana M. Napalkova

The paper presents the aspects of the toxicity, specific activity, pharmacokinetics and pharmacodynamics of aceclofenac, given in various sources describing its preclinical studies. The search for information sources for the study was carried out using domestic and international databases: elibrary and PubMed using contextual queries, including terms of the international nonproprietary name, preclinical studies of pharmacokinetics, pharmacodynamics, and animal species. Aceclofenac is one of the most prescribed drugs for acute and chronic pain. It refers to non-steroidal anti-inflammatory drugs, considered as drugs of first choice in the treatment of inflammation and pain. On the pharmaceutical market of the Russian Federation, aceclofenac is presented in the form of tablets, powder for suspension preparation, cream for external use, which allows it to be prescribed for various diseases. It has shown itself to be highly effective in the symptomatic treatment of diseases of the musculoskeletal system, for the relief of acute and chronic pain. A review of preclinical studies materials cited in various literature sources and including aspects of studying the toxicity, specific activity, pharmacokinetics and pharmacodynamics of aceclofenac, in our opinion, will allow using the data obtained in our study as one of the tools for further registration of generics.


Pain medicine ◽  
2019 ◽  
Vol 4 (1) ◽  
pp. 22-36
Author(s):  
D V Dmytriiev ◽  
O A Zaletska ◽  
D I Bortnik

After reading this article, the reader will be familiar with the general classes of opioid agonists and partial agonists, the basics of the pharmacokinetics and pharmacodynamics of opioids, the risks of opioid therapy and the requirements for the safe and effective use of opioids in acute and chronic pain. The use of opioids during surgical procedures or anesthesia is not discussed. Also, there is no discussion about various available opioid antagonists that are used to treat overdose and the various disorders associated with their use (including naloxone and naltrexone). Opioids are available, the most powerful and effective analgesics, and have become acceptable drugs for the treatment of acute and cancerous pain. However, there is concern about their use in case of chronic pain, if there is no cancer, because they are long-range ineffective but best suited for stopping this pain. Opioid prescription must be monitored for better use. Chronic pain creates discomfort for these patients, reducing their productivity and efficiency, which, in turn, can lead to economic problems in the country. The choice of Nalbuphine is due to the following reasons: the opioid, which is comparable to morphine by its analgesic potential, but has a better safety profile for nausea, vomiting and respiratory depression; not subject to strict quantitative accounting (extract on prescription form 1); the choice of opioid analgesics is significantly limited in Ukraine.


2000 ◽  
Vol 27 (10) ◽  
pp. 834-841 ◽  
Author(s):  
O. Plesh ◽  
D. Curtis ◽  
J. Levine ◽  
W. D. Mccall Jr

2020 ◽  
Vol 47 (6) ◽  
pp. 855.e11-855.e12
Author(s):  
H. Trenholme ◽  
A. Hanafi ◽  
R. Reed ◽  
D. Sakai ◽  
C. Ryan ◽  
...  

Ob Gyn News ◽  
2005 ◽  
Vol 40 (10) ◽  
pp. 34
Author(s):  
SHERRY BOSCHERT
Keyword(s):  

2005 ◽  
Vol 38 (13) ◽  
pp. 12
Author(s):  
COLIN NELSON
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document